Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W F Symmans

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapyL Du, C Yau, L Brown-Swigart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2014
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014R Salgado, C Denkert, S Demaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2022
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trialsM Marczyk, A Mrukwa, C Yau, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapyL Du, C Yau, L Brown-Swigart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2014
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014R Salgado, C Denkert, S Demaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2022
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trialsM Marczyk, A Mrukwa, C Yau, et al.
Pageof 6